


# BETTER EDUCATION ON GLOMERULAR DISEASE: IMPROVING DIAGNOSIS AND TREATMENT OF C3 GLOMERULOPATHY



This program was recorded on November 9, 2022. To obtain CE credit [click here](#).

## Clinical Resources

### Guidelines

KDIGO Workgroup. KDIGO 2021 Clinical Practice Guideline for Management of Glomerular Diseases. *Kidney Int.* 2021;100(4S):S1-S276.

### Pivotal Articles

Chadban SJ, Atkins RC. Glomerulonephritis. *Lancet.* 2005;365(9473):1797-1806.

Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy – understanding a rare complement-driven renal disease. *Nat Rev Nephrol.* 2019;15(3):129-143.

Ahmad SB, Bomback AS. C3 glomerulopathy: Pathogenesis and treatment. *Adv Chronic Kidney Dis.* 2020;27(2):104-110.

Riedl M, Thorner P, Licht C. C3 glomerulopathy. *Pediatr Nephrol.* 2017;32(1):43-57.

Master Sankar Raj V, Gordillo R, Chand DH, et al. Overview of C3 glomerulopathy. *Front Pediatr.* 2016;4(May 6):45.

### Clinical Trials

APPEAR-C3G (iptacopan). [Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy](#)

NOBLE (pegcetacoplan). [Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN](#)

VALIANT (pegcetacoplan). [Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis](#)

### Patient Education

US Food and Drug Administration. Voice of the Patient. Published March 26, 2018. Accessed October 1, 2022. [https://www.kidney.org/sites/default/files/C3G\\_EL-PFDD\\_VoP-Report\\_3-29-18.pdf](https://www.kidney.org/sites/default/files/C3G_EL-PFDD_VoP-Report_3-29-18.pdf)

National Organization for Rare Disorders, Inc. [C3 Glomerulopathy: Dense Deposit Disease and C3 Glomerulonephritis](#)

National Kidney Foundation. [Complement 3 Glomerulopathy \(C3G\)](#)

Nephcure Kidney International. [C3 Glomerulopathy \(MPGN\)](#)